

Capecitabine compared with observation in resected b
randomised, controlled, multicentre, phase 3 study

Lancet Oncology, The

20, 663-673

DOI: [10.1016/s1470-2045\(18\)30915-x](https://doi.org/10.1016/s1470-2045(18)30915-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. <i>Cancers</i> , 2018, 10, 283.	1.7	44
2	Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: A multicenter study. <i>Surgery</i> , 2019, 166, 975-982.	1.0	46
3	Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma. <i>Scientific Reports</i> , 2019, 9, 11770.	1.6	19
4	Targeted therapy for cholangiocarcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 661-662.	3.7	3
5	Surgery for Hilar cholangiocarcinoma: the Newcastle upon Tyne Liver Unit experience. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2019, 51, 197-205.	0.3	2
6	Selecting treatment sequence for patients with incidental gallbladder cancer: a neoadjuvant approach versus upfront surgery. <i>Updates in Surgery</i> , 2019, 71, 217-225.	0.9	11
7	Author response to comment on: Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. <i>British Journal of Surgery</i> , 2019, 106, 1101-1102.	0.1	0
8	Comment on: Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. <i>British Journal of Surgery</i> , 2019, 106, 1100-1101.	0.1	0
9	Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 124-129.	2.0	19
10	Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2121-2137.	0.9	7
11	Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2019, 71, 1261-1262.	1.8	17
12	Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation?. <i>Annals of Surgical Oncology</i> , 2019, 26, 2959-2968.	0.7	43
13	Adjuvant capecitabine in biliary tract cancer: a standard option?. <i>Lancet Oncology</i> , The, 2019, 20, 606-608.	5.1	26
14	In the literature: June 2019. <i>ESMO Open</i> , 2019, 4, e000547.	2.0	3
15	Genomic Characterization of <i>ERBB2</i> -Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	23
16	Systemic management for patients with hepatobiliary tumors in a multi-dimensional view. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 626-628.	0.7	6
17	The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery. <i>Cancer Management and Research</i> , 2019, Volume 11, 10871-10882.	0.9	4
18	Contemporary Tailored Oncology Treatment of Biliary Tract Cancers. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-15.	0.7	5

#	ARTICLE	IF	CITATIONS
19	The role of ALPPS in intrahepatic cholangiocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 885-894.	0.8	19
20	Gallbladder Cancer. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 619-630.	0.6	22
21	Approaches and Outcomes to Distal Cholangiocarcinoma. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 631-643.	0.6	14
22	Systemic Therapy for Primary Liver Tumors. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 695-715.	0.6	9
23	Failure patterns after curative resection for intrahepatic cholangiocarcinoma: possible implications for postoperative radiotherapy. <i>BMC Cancer</i> , 2019, 19, 1108.	1.1	3
24	Re-resection for incidentally detected gallbladder cancer: Weighing in on the options. <i>European Journal of Surgical Oncology</i> , 2020, 46, 495-497.	0.5	6
25	Comparison of short- and long-term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high-volume center. <i>Hpb</i> , 2020, 22, 405-414.	0.1	12
26	Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 552-560.	0.7	25
27	Advanced hilar cholangiocarcinoma: An aggressive surgical approach for the treatment of advanced hilar cholangiocarcinoma: Perioperative management, extended procedures, and multidisciplinary approaches. <i>Surgical Oncology</i> , 2020, 33, 201-206.	0.8	37
28	Moving the Needle Forward With Locoregional Treatment in Unresectable Cholangiocarcinomaâ€”The Jury Is Still Out. <i>JAMA Oncology</i> , 2020, 6, 29.	3.4	7
29	Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 51.	3.4	176
31	Incidental Gallbladder Cancer: Permission to Operate. <i>Annals of Surgical Oncology</i> , 2020, 27, 980-982.	0.7	5
32	Prognostic factors and patterns of loco-regional failure in patients with R0 resected gallbladder cancer. <i>Hpb</i> , 2020, 22, 1168-1173.	0.1	2
33	Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer â€” Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort. <i>European Journal of Surgical Oncology</i> , 2020, 46, 804-810.	0.5	18
34	Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. <i>Pharmacological Research</i> , 2020, 152, 104594.	3.1	17
35	Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization. <i>Journal of Clinical Medicine</i> , 2020, 9, 56.	1.0	35
36	Resection and chemotherapy is the optimal treatment approach for patients with clinically node positive intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2020, 22, 129-135.	0.1	7
37	Reply to â€œComment on: Adjuvant Chemotherapy in Resectable Gallbladder Cancer is Underutilized Despite Benefits in Node-Positive Patientsâ€”, <i>Annals of Surgical Oncology</i> , 2020, 27, 942-943.	0.7	3

#	ARTICLE	IF	CITATIONS
38	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021, 73, 2311-2325.	3.6	40
39	Recent developments and ongoing trials in transplant oncology. <i>Liver International</i> , 2020, 40, 2326-2344.	1.9	6
40	Overview of current targeted therapy in gallbladder cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 230.	7.1	84
41	Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. <i>Annals of Oncology</i> , 2020, 31, 1169-1177.	0.6	70
42	Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1353-1363.	0.6	22
43	Failure to administer multimodality therapy leads to sub-optimal outcomes for patients with node-positive biliary tract cancers in the United States. <i>Surgical Oncology</i> , 2020, 34, 298-303.	0.8	3
44	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	2.9	37
45	Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. <i>JAMA Oncology</i> , 2020, 6, e202701.	3.4	27
46	About the Recently Published Paper on <i>JAMA Oncology</i> "Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial" CardioVascular and Interventional Radiology, 2020, 43, 1418-1419.	0.9	0
47	Adjuvant treatments in biliary tract cancer: an analysis based on restricted mean survival time. <i>Digestive and Liver Disease</i> , 2020, 52, 1208-1209.	0.4	1
48	Adjuvant Chemotherapy in Resected Biliary Tract Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 2127-2129.	0.7	0
49	Role of adjuvant (chemo)radiotherapy for resected extrahepatic cholangiocarcinoma: a meta-analysis. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 549-559.	1.3	7
50	In Vivo Models for Cholangiocarcinoma "What Can We Learn for Human Disease?". <i>International Journal of Molecular Sciences</i> , 2020, 21, 4993.	1.8	8
51	Adjuvant chemoradiotherapy for positive hepatic ductal margin on cholangiocarcinoma. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 455-463.	1.2	10
52	Subtleties in the interpretation of hazard contrasts. <i>Lifetime Data Analysis</i> , 2020, 26, 833-855.	0.4	55
54	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. <i>Cancers</i> , 2020, 12, 3370.	1.7	28
55	In Reply. <i>Oncologist</i> , 2020, 25, e1819.	1.9	0
56	Intrahepatic cholangiocarcinoma with gastric infiltration misdiagnosed as gastric submucosal tumor. <i>Journal of Surgical Case Reports</i> , 2020, 2020, rjaa359.	0.2	2

#	ARTICLE	IF	CITATIONS
57	ASO Author Reflections: Adjuvant Chemoradiation for Patients with Resected Biliary Tract Cancers. <i>Annals of Surgical Oncology</i> , 2020, 27, 5173-5174.	0.7	1
58	Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial. <i>Cancers</i> , 2020, 12, 1975.	1.7	17
59	Malignant liver tumours. <i>Surgery</i> , 2020, 38, 480-486.	0.1	2
60	Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancers. <i>Hpb</i> , 2020, 22, 939-949.	0.1	9
61	A Novel Nomogram Predicting Distant Metastasis in T1 and T2 Gallbladder Cancer: A SEER-based Study. <i>International Journal of Medical Sciences</i> , 2020, 17, 1704-1712.	1.1	15
62	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	0.7	4
63	A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01). <i>BMC Cancer</i> , 2020, 20, 688.	1.1	8
64	Clinicopathological and prognostic implications of vessels encapsulate tumor clusters with PD-L1 in intrahepatic cholangiocarcinoma patients. <i>Translational Cancer Research</i> , 2020, 9, 3550-3563.	0.4	4
65	Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. <i>Cancers</i> , 2020, 12, 2190.	1.7	38
66	Lung metastases from intraductal papillary neoplasm of the bile duct: a case report. <i>World Journal of Surgical Oncology</i> , 2020, 18, 271.	0.8	3
67	Prognostic Significance of Tumor Location in T2 Gallbladder Cancer: A Korea Tumor Registry System Biliary Pancreas (KOTUS-BP) Database Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3268.	1.0	13
68	Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy. <i>ESMO Open</i> , 2020, 5, e000770.	2.0	17
70	A review of systemic therapy in biliary tract carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 770-789.	0.6	14
72	Textbook Outcomes Following Liver Resection for Cancer: A New Standard for Quality Benchmarking and Patient Decision Making. <i>Annals of Surgical Oncology</i> , 2020, 27, 3118-3120.	0.7	13
73	Chemoradiation for Patients with Resected Biliary Tract Cancers in the Adjuvant Setting: Reply to a Letter to the Editor. <i>Annals of Surgical Oncology</i> , 2020, 27, 937-939.	0.7	0
74	Comparative Outcomes of Adenosquamous Carcinoma of the Gallbladder: an Analysis of the National Cancer Database. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1815-1827.	0.9	13
75	Prognostic impact of lymphovascular invasion in pT1-3 gallbladder adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 122, 1401-1408.	0.8	6
76	Patterns of Failure and Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 4867-4869.	0.7	0

#	ARTICLE	IF	CITATIONS
77	Effect of Margin Status on Survival After Resection of Hilar Cholangiocarcinoma in the Modern Era of Adjuvant Therapies. <i>American Surgeon</i> , 2021, 87, 1496-1503.	0.4	7
78	Locoregional therapies in patients with recurrent intrahepatic cholangiocarcinoma after curative resection. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097697.	1.4	3
79	Intrahepatic Cholangiocarcinoma. <i>Seminars in Interventional Radiology</i> , 2020, 37, 475-483.	0.3	8
80	The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 604387.	1.3	14
81	Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients. <i>Cancers</i> , 2020, 12, 3670.	1.7	12
82	Strategies for the Delay of Surgery in the Management of Resectable Hepatobiliary Malignancies during the COVID-19 Pandemic. <i>Current Oncology</i> , 2020, 27, 501-511.	0.9	16
83	Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 577-586.	0.7	14
84	Multi-modal and sequential treatment of liver cancer and its impact on the gastrointestinal tract. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 48-49, 101709.	1.0	2
85	Time to Recurrence After Surgical Resection and Survival After Recurrence Among Patients with Perihilar and Distal Cholangiocarcinomas. <i>Annals of Surgical Oncology</i> , 2020, 27, 4171-4180.	0.7	21
86	Biliary Tract Cancer: Current Medical Treatment Strategies. <i>Cancers</i> , 2020, 12, 1237.	1.7	43
87	Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status. <i>BMC Cancer</i> , 2020, 20, 405.	1.1	16
88	The Landmark Series: Gallbladder Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 2846-2858.	0.7	36
89	Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102975.	2.0	14
90	Effect of lymphadenectomy in curative gallbladder cancer treatment: a systematic review and meta-analysis. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 573-584.	0.8	13
91	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 147, 3177-3188.	2.3	17
92	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. <i>Medical Oncology</i> , 2020, 37, 61.	1.2	9
93	Extended liver surgery for gallbladder cancer revisited: Is there a role for hepatopancreatoduodenectomy?. <i>International Journal of Surgery</i> , 2020, 82, 82-86.	1.1	9
94	Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives. <i>Current Opinion in Oncology</i> , 2020, 32, 364-369.	1.1	7

#	ARTICLE	IF	CITATIONS
95	A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. <i>BMC Cancer</i> , 2020, 20, 515.	1.1	10
96	Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3729-3737.	0.7	56
97	Reaching out beyond first-line treatments in advanced biliary tract cancers. <i>Annals of Oncology</i> , 2020, 31, 1099-1102.	0.6	1
98	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 765-775.	3.7	33
99	Phase 2 Trial of Adjuvant Chemotherapy With Sâ€™%â€™â€™1 for Node-Positive Biliary Tract Cancer (N-SOG 09). <i>Annals of Surgical Oncology</i> , 2020, 27, 2348-2356.	0.7	15
100	Molecular targeted therapies: Ready for â€™prime timeâ€™ in biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 170-185.	1.8	226
101	Neoadjuvant chemoradiotherapy before resection of perihilar cholangiocarcinoma: A systematic review. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2020, 19, 103-108.	0.6	18
102	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 73, 315-327.	1.8	164
103	Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) â€™ a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)â€™ the AIO/ CALGP/ ACO- GAIN-trial â€™. <i>BMC Cancer</i> , 2020, 20, 122.	1.1	45
104	Tumour budding and its clinical implications in gastrointestinal cancers. <i>British Journal of Cancer</i> , 2020, 123, 700-708.	2.9	36
105	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
106	Cholangiocarcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 421-436.	1.0	17
108	Clinicopathological Characteristics and Surgical Outcomes of Primary Cystic Duct Carcinoma: A Multiâ€™institutional Study. <i>World Journal of Surgery</i> , 2020, 44, 3875-3883.	0.8	6
109	Relevant Clinical Trials for GI Surgeons: a Review of Recent Findings. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2318-2335.	0.9	0
110	Cholangiocarcinoma: three different entities based on location. <i>Annals of Translational Medicine</i> , 2020, 8, 738-738.	0.7	2
112	Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much better. <i>Current Opinion in Oncology</i> , 2020, 32, 344-346.	1.1	0
113	Disparities in Treatment for Gallbladder Carcinoma: Does Treatment Site Matter?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1071-1076.	0.9	9
114	Prognostic impact of the Bismuth-Corlette classification: Higher rates of local unresectability in stage IIIb hilar cholangiocarcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2020, 19, 157-162.	0.6	6

#	ARTICLE	IF	CITATIONS
115	Gastrointestinal Cancers: Moving the Needle for Rectal, Gastroesophageal, Pancreaticobiliary, and Liver Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 653-662.	0.4	1
116	Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?. <i>Annals of Oncology</i> , 2020, 31, 447-448.	0.6	2
117	Laparoscopic liver resection versus open liver resection for intrahepatic cholangiocarcinoma: 3-year outcomes of a cohort study with propensity score matching. <i>Surgical Oncology</i> , 2020, 33, 63-69.	0.8	25
119	Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 1908-1917.	0.7	7
120	Liver resection and transplantation for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 72, 364-377.	1.8	177
121	Survival improvement and prognostic factors in recent management of extrahepatic cholangiocarcinoma: A single-center study. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2020, 19, 153-156.	0.6	3
122	Milestones in the pathogenesis and management of primary liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 209-214.	1.8	39
123	A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma. <i>Radiation Oncology</i> , 2020, 15, 15.	1.2	31
124	Advances in the treatment of biliary tract cancers. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 1.	1.0	10
126	Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 149, 102940.	2.0	5
127	A case of chest wall recurrence of hilar cholangiocarcinoma 10 years after R1 surgery with positive ductal margin of carcinoma in situ. <i>International Cancer Conference Journal</i> , 2020, 9, 77-81.	0.2	0
128	Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 148, 194-200.	0.3	43
129	Primary Liver Cancers. <i>Surgical Clinics of North America</i> , 2020, 100, 535-549.	0.5	54
130	ASO Author Reflections: Phase II Trial of Adjuvant Chemotherapy with S-1 for Node-Positive Biliary Tract Cancer (N-SOG 09). <i>Annals of Surgical Oncology</i> , 2020, 27, 2357-2358.	0.7	1
131	Treatment of Combined Hepatocellular and Cholangiocarcinoma. <i>Cancers</i> , 2020, 12, 794.	1.7	32
132	Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort. <i>Cancers</i> , 2020, 12, 918.	1.7	18
133	Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. <i>Cancer Treatment Reviews</i> , 2020, 86, 101998.	3.4	25
134	Surgical Treatments of Hepatobiliary Cancers. <i>Hepatology</i> , 2021, 73, 128-136.	3.6	99

#	ARTICLE	IF	CITATIONS
135	Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review. <i>Current Problems in Cancer</i> , 2021, 45, 100614.	1.0	14
136	Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1156-1163.	0.9	20
137	ASO Author Reflection: Trends and Impact of Adjuvant Chemotherapy in Resected Gallbladder Cancer: Going Beyond Trial Data. <i>Annals of Surgical Oncology</i> , 2021, 28, 1481-1482.	0.7	1
138	Adjuvant Chemotherapy in Resectable Gallbladder Cancer is Underutilized Despite Benefits in Node-Positive Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 1466-1480.	0.7	16
139	Extended Resections for Advanced Gallbladder Cancer: Results from a Nationwide Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 835-843.	0.7	15
140	Outcomes in older patients with biliary tract cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 569-575.	0.5	5
141	Surgical management of biliary malignancy. <i>Current Problems in Surgery</i> , 2021, 58, 100854.	0.6	4
142	Repeated resection for recurrent intrahepatic cholangiocarcinoma: A retrospective German multicentre study. <i>Liver International</i> , 2021, 41, 180-191.	1.9	20
143	Prognostic Utility of the Glasgow Prognostic Score for the Long-Term Outcomes After Liver Resection for Intrahepatic Cholangiocarcinoma: A Multi-Institutional Study. <i>World Journal of Surgery</i> , 2021, 45, 279-290.	0.8	5
144	Prognostic Impact of Paraaortic Lymph Node Metastasis in Extrahepatic Cholangiocarcinoma. <i>World Journal of Surgery</i> , 2021, 45, 581-589.	0.8	5
145	Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 365-375.	1.9	10
146	Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2021, 28, 1970-1978.	0.7	30
147	The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 281-284.	1.9	7
148	Recent advances of immunotherapy for biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 527-536.	1.4	85
149	Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. <i>Advances in Cancer Research</i> , 2021, 149, 321-387.	1.9	18
150	Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 4018-4029.	0.7	11
151	Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis. <i>Cancer</i> , 2021, 127, 1266-1274.	2.0	9
152	Experimental HER2- targeted therapies for biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 389-399.	1.9	9

#	ARTICLE	IF	CITATIONS
153	Reassessing the role of surgery in the elderly or chronically sick with proximal extrahepatic cholangiocarcinoma. <i>Surgery</i> , 2021, 169, 233-239.	1.0	5
154	Characteristics and survival prognosis of patients with pure squamous cell carcinoma of the gallbladder. <i>ANZ Journal of Surgery</i> , 2021, 91, E91-E97.	0.3	4
155	Surgical Approach to Recurrent Cholangiocarcinoma. <i>Visceral Medicine</i> , 2021, 37, 26-31.	0.5	6
156	The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. <i>International Journal of Medical Sciences</i> , 2021, 18, 187-198.	1.1	14
157	Gallbladder Cancer Surgery in the United States: Lymphadenectomy Trends and Impact on Survival. <i>Journal of Surgical Research</i> , 2021, 258, 54-63.	0.8	7
158	The impact of peritoneal lavage cytology in biliary tract cancer (<sc>KHBO1701</sc>): Kansai <sc>Hepato&Biliary</sc> Oncology Group. <i>Cancer Reports</i> , 2021, 4, e1323.	0.6	6
159	BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 483-485.	1.4	37
160	Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 417-425.	0.7	21
161	The implications of treatment delays in adjuvant therapy for cholangiocarcinoma patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 291-291.	0.8	2
162	Progress Toward Improving Outcomes in Patients with Cholangiocarcinoma. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 153-168.	0.3	1
163	Significance of proximal ductal margin status after resection of hilar cholangiocarcinoma. <i>Hpb</i> , 2021, 23, 109-117.	0.1	6
164	Neoadjuvant Therapy and Conversion Surgery for Cholangiocarcinoma. , 2021, , 143-155.		0
165	Cholangiocarcinoma: a review of the literature and future directions in therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 555-566.	0.7	17
166	Adjuvant Chemotherapy for Cholangiocarcinoma. , 2021, , 133-142.		0
167	A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: An analysis of the National Cancer Database. <i>Journal of Surgical Oncology</i> , 2021, 123, 949-956.	0.8	22
168	Identification of patients who may benefit the most from adjuvant chemotherapy following resection of incidental gallbladder carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 978-985.	0.8	7
169	Biliary tract cancer. <i>Lancet, The</i> , 2021, 397, 428-444.	6.3	429
170	Raised carbohydrate antigen 19-9 levels detect recurrences and impacts overall and disease-free survival in radically resected gallbladder cancer: A simple surveillance marker?. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 273.	0.3	2

#	ARTICLE	IF	CITATIONS
171	First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!" Cancer Treatment and Research Communications, 2021, 27, 100335.	0.7	55
172	A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System. Cells, 2021, 10, 70.	1.8	8
173	Efficacy Analysis of Adjuvant Chemotherapy with Gemcitabine Plus Platinum or S-1 in Biliary Tract Carcinoma: A Multi-Center Retrospective Study. Cancer Management and Research, 2021, Volume 13, 889-898.	0.9	0
174	Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control, 2021, 28, 107327482110099.	0.7	4
175	Laparoscopic <i>versus</i> open resection of intrahepatic cholangiocarcinoma: nationwide analysis. British Journal of Surgery, 2021, 108, 419-426.	0.1	32
176	Transhepatic Direct Approach to the "Limit of the Division of the Hepatic Ducts" Leads to a High R0 Resection Rate in Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 2358-2367.	0.9	6
177	Outcome of radical surgery for gallbladder carcinoma according to TNM stage: implications for adjuvant therapeutic strategies. Langenbeck's Archives of Surgery, 2021, 406, 801-811.	0.8	4
178	A Tool for Patient-Focused Care Regarding Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 1874-1875.	0.7	3
180	Prognosis and Survival in Gall Bladder Cancer. , 2021, , 247-259.		0
181	A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada. Current Oncology, 2021, 28, 417-427.	0.9	6
182	Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treatment and Research Communications, 2021, 27, 100354.	0.7	36
183	Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Annals of Surgical Oncology, 2021, 28, 1939-1949.	0.7	31
184	The prognostic impact of peritoneal washing cytology for otherwise resectable extrahepatic cholangiocarcinoma patients. Surgery Today, 2021, 51, 1227-1231.	0.7	1
185	Adjuvant Therapy in Resected Nonmetastatic Stage II-IV Gallbladder Cancer: A Generalized Propensity Score Analysis. Oncology Research and Treatment, 2021, 44, 390-399.	0.8	4
186	Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treatment and Research Communications, 2021, 27, 100337.	0.7	57
187	Surgical Approach to the Treatment of Cholangiocarcinoma. , 2021, , 319-338.		0
188	Examining the Use of Radiation Therapy for Cholangiocarcinoma: Benefits through Modern Techniques. Oncology Research and Treatment, 2021, 44, 408-413.	0.8	0
189	ASO Author Reflections: Contemporary Analysis of Impact of Lymphadenectomy on Survival in Nonmetastatic Gallbladder Cancer. Annals of Surgical Oncology, 2021, 28, 2973-2974.	0.7	0

#	ARTICLE	IF	CITATIONS
190	Is there any place for novel agents in treating biliary tract cancer?. <i>Medical Oncology</i> , 2021, 38, 19.	1.2	1
191	Rates, Predictors, and Outcomes of Portal Lymphadenectomy for Resectable Gallbladder Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2960-2972.	0.7	8
192	Validation of the 8th Edition American Joint Commission on Cancer (AJCC) Gallbladder Cancer Staging System: Prognostic Discrimination and Identification of Key Predictive Factors. <i>Cancers</i> , 2021, 13, 547.	1.7	24
193	Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 547-554.	1.4	52
194	Gallbladder carcinoma outcomes in an Australian tertiary referral hospital. <i>ANZ Journal of Surgery</i> , 2021, 91, 603-608.	0.3	3
196	Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. <i>Annals of Surgical Oncology</i> , 2021, 28, 6725-6735.	0.7	23
197	The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 925.	1.0	3
198	EVOLUTION OF TREATMENT OF CANCER OF THE MAJOR DUODENAL PAPANILLA. <i>Siberian Journal of Oncology</i> , 2021, 20, 141-148.	0.1	0
199	Should all intrahepatic cholangiocarcinomas receive neoadjuvant chemotherapy before resection?. <i>British Journal of Surgery</i> , 2021, 108, 598-599.	0.1	5
200	Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 600027.	1.3	3
201	The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. <i>Annals of Surgical Oncology</i> , 2021, 28, 2660-2674.	0.7	38
202	Baicalein mediates anticancer effect on cholangiocarcinoma through co-targeting the AKT/NF- κ B and STAT3 signaling pathway. <i>Process Biochemistry</i> , 2021, 102, 304-314.	1.8	8
203	Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1054-1064.	13.9	2
204	Surgical management of intrahepatic cholangiocarcinoma: a narrative review. <i>Digestive Medicine Research</i> , 0, 4, 4-4.	0.2	2
205	SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 988-1000.	1.2	23
206	Underutilization of Lymphadenectomy for Gallbladder Cancer: A Persistent Problem with Dire Consequences. <i>Annals of Surgical Oncology</i> , 2021, 28, 2928-2930.	0.7	0
207	External beam radiation treatment of intrahepatic cholangiocarcinoma: a narrative review. <i>Digestive Medicine Research</i> , 0, 4, 12-12.	0.2	2
208	Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis. <i>Oncogene</i> , 2021, 40, 2910-2922.	2.6	13

#	ARTICLE	IF	CITATIONS
210	Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2815-2819.	1.0	2
211	Early Recurrence Following Resection of Distal Cholangiocarcinoma: A New Tool for the Toolbox. <i>Annals of Surgical Oncology</i> , 2021, 28, 4069-4071.	0.7	4
212	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. <i>Vaccines</i> , 2021, 9, 422.	2.1	8
213	The prognostic role of tumor-associated unilateral portal vein occlusion in perihilar cholangiocarcinoma. <i>Hpb</i> , 2021, 23, 1565-1577.	0.1	3
214	Synergistic impact of resection margin and microscopic vascular invasion for patients with HBV-related intrahepatic cholangiocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 575-582.	1.4	8
215	Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. <i>Cancers</i> , 2021, 13, 1647.	1.7	10
217	FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 567-574.	1.4	7
218	Gallbladder cancer of two histological origins: A case report and review of literature. <i>International Journal of Surgery Case Reports</i> , 2021, 81, 105704.	0.2	2
219	Surgical morbidity in the first year after resection for perihilar cholangiocarcinoma. <i>Hpb</i> , 2021, 23, 1607-1614.	0.1	11
220	Cholangiocarcinoma: is it time for a revolution?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 467-470.	1.4	1
221	Current progress in systemic therapy for biliary tract cancers. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, , .	1.4	6
222	Ivosidenib: an investigational drug for the treatment of biliary tract cancers. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 301-307.	1.9	5
223	Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center. <i>Cancers</i> , 2021, 13, 2070.	1.7	6
224	Primary clear cell carcinoma of gallbladder arising in porcelain gallbladder. <i>BMJ Case Reports</i> , 2021, 14, e240319.	0.2	2
225	The Landmark Series: Hilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4158-4170.	0.7	30
226	Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 217-224.	0.4	0
227	Anatomic location of residual disease after initial cholecystectomy independently determines outcomes after re-resection for incidental gallbladder cancer. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 1521-1532.	0.8	4
228	Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 537-545.	1.4	7

#	ARTICLE	IF	CITATIONS
229	Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. <i>Cancers</i> , 2021, 13, 2358.	1.7	9
231	Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma. <i>Liver Cancer</i> , 2021, 10, 260-274.	4.2	14
232	Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 475-481.	1.4	2
233	Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. <i>Clinical Cancer Research</i> , 2021, 27, 4101-4108.	3.2	24
234	Disparities in NCCNÂGuidelineÂCompliant Care for Resectable Cholangiocarcinoma at Minority-Serving Versus Non-Minority-Serving Hospitals. <i>Annals of Surgical Oncology</i> , 2021, 28, 8162-8171.	0.7	16
236	Investigation of a Tumor Location-Specific Therapeutic Strategy for Intrahepatic Cholangiocarcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1485-1493.	0.5	5
237	Management of Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2368.	1.0	14
238	The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2428.	1.0	4
239	Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study. <i>Scientific Reports</i> , 2021, 11, 12166.	1.6	14
240	Adjuvant Sâ€1 vs gemcitabine for nodeâ€positive perihilar cholangiocarcinoma: A propensity scoreâ€adjusted analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 716-726.	1.4	12
242	Distal Bile Duct Cancer. <i>Annals of Surgery</i> , 2021, Publish Ahead of Print, .	2.1	1
243	Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey. <i>Hepatology Research</i> , 2021, 51, 890-901.	1.8	5
244	Laparoscopic Surgery for Intrahepatic Cholangiocarcinoma: A Focus on Oncological Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 2828.	1.0	11
245	Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. <i>American Journal of Surgery</i> , 2021, 221, 1182-1187.	0.9	16
246	Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2803.	1.0	14
247	Re-appraising the role of lymph node status in predicting survival in resected distal cholangiocarcinoma â€ A meta-analysis and systematic review. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1267-1277.	0.5	5
248	Long Non-coding RNA FIRRE Acts as a miR-520a-3p Sponge to Promote Gallbladder Cancer Progression via Mediating YOD1 Expression. <i>Frontiers in Genetics</i> , 2021, 12, 674653.	1.1	11
249	Intraoperative indocyanine green-visualization in a difficult to localize central cholangiocarcinoma â€ A case report. <i>International Journal of Surgery Case Reports</i> , 2021, 83, 105973.	0.2	0

#	ARTICLE	IF	CITATIONS
250	A tailored approach in lymph node-positive perihilar cholangiocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 1499-1509.	0.8	15
251	Prognostic Significance of Tumor Location in T2 Gallbladder Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3317.	1.0	5
252	The Presence of Small Nerve Fibers in the Tumor Microenvironment as Predictive Biomarker of Oncological Outcome Following Partial Hepatectomy for Intrahepatic Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 3661.	1.7	10
253	Therapeutic challenges at the preclinical level for targeted drug development for <i>Opisthorchis viverrini</i> -associated cholangiocarcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 985-1006.	1.9	3
254	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103328.	2.0	25
255	Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection. <i>World Journal of Surgical Oncology</i> , 2021, 19, 218.	0.8	10
256	Chemotherapy for Biliary Tract Cancer in 2021. <i>Journal of Clinical Medicine</i> , 2021, 10, 3108.	1.0	22
257	Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?. <i>World Journal of Gastroenterology</i> , 2021, 27, 4252-4275.	1.4	4
258	Gallbladder cancer epidemiology, treatment and survival in Southern Finland – a population-based study. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 929-939.	0.6	5
259	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. <i>Acta Oncologica</i> , 2021, 60, 1317-1324.	0.8	2
260	FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. <i>Current Oncology Reports</i> , 2021, 23, 108.	1.8	23
261	Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 3657.	1.7	55
263	Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening. <i>Cells</i> , 2021, 10, 2077.	1.8	6
264	GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. <i>Gut</i> , 2022, 71, 1386-1398.	6.1	28
266	The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101788.	0.7	3
267	Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 498-506.	0.7	10
268	Liver Resection for Intrahepatic Cholangiocarcinoma – Single-Center Experience with 286 Patients Undergoing Surgical Exploration over a Thirteen Year Period. <i>Journal of Clinical Medicine</i> , 2021, 10, 3559.	1.0	7
269	Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 4062.	1.7	7

#	ARTICLE	IF	CITATIONS
270	Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 515-517.	0.7	1
271	Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021, 99, 1-10.	0.9	0
273	The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review. <i>European Journal of Surgical Oncology</i> , 2022, 48, 150-159.	0.5	19
274	Vascular Resection for Intrahepatic Cholangiocarcinoma: Current Considerations. <i>Journal of Clinical Medicine</i> , 2021, 10, 3829.	1.0	4
275	Adjuvant radiotherapy improves long-term survival after resection for gallbladder cancer A population-based cohort study. <i>European Journal of Surgical Oncology</i> , 2022, 48, 425-434.	0.5	7
276	The effect of patient sex on the efficacy and safety of anticancer immunotherapy. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1535-1544.	1.0	10
277	Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects. <i>World Journal of Surgical Oncology</i> , 2021, 19, 280.	0.8	2
278	Analysis of Post-operative Adjuvant Chemotherapy Versus Adjuvant Chemoradiation Therapy Outcomes in Non-metastatic Cholangiocarcinoma: an NCDB Review. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	0.6	0
279	Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. <i>Cancer Science</i> , 2021, 112, 4819-4833.	1.7	4
281	Biliary Strictures and Cholangiocarcinoma – Untangling a Diagnostic Conundrum. <i>Frontiers in Oncology</i> , 2021, 11, 699401.	1.3	9
282	Cholangiocarcinoma Therapeutics: An Update. <i>Current Cancer Drug Targets</i> , 2021, 21, 457-475.	0.8	5
283	Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2021, 12, 2075-2088.	0.8	11
284	The prognostic role of in-hospital transfusion of fresh frozen plasma in patients with cholangiocarcinoma undergoing curative-intent liver surgery. <i>European Journal of Surgical Oncology</i> , 2022, 48, 604-614.	0.5	4
285	Approach to Resectable Biliary Cancers. <i>Current Treatment Options in Oncology</i> , 2021, 22, 97.	1.3	6
286	Efficacy and Feasibility of Adjuvant Gemcitabine Plus Cisplatin Chemotherapy After Major Hepatectomy for Biliary Tract Cancer. <i>Anticancer Research</i> , 2021, 41, 5231-5240.	0.5	0
287	Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1073-1085.	0.8	4
288	Cholangiocarcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 65.	18.1	270
289	Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. <i>The Cochrane Library</i> , 2021, CD012814.	1.5	17

#	ARTICLE	IF	CITATIONS
290	Causality and the Cox Regression Model. <i>Annual Review of Statistics and Its Application</i> , 2022, 9, 249-259.	4.1	10
292	Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 657-671.	0.6	0
293	Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2525-2532.	0.5	21
294	Medical therapies for intra-hepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021, 75, 981-983.	1.8	7
295	The Role of Adjuvant Chemoradiotherapy in Nonhilar Extrahepatic Bile Duct Cancer: A Long-Term Single-Institution Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 395-404.	0.4	4
296	Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14). <i>European Journal of Cancer</i> , 2021, 157, 31-39.	1.3	5
297	IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100356.	0.7	18
298	Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis. <i>Liver Cancer</i> , 2021, 10, 419-432.	4.2	4
299	Current and Future Systemic Therapies in Biliary Tract Cancer. <i>Visceral Medicine</i> , 2021, 37, 32-38.	0.5	5
303	Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100334.	0.7	9
304	Adjuvant radiotherapy and chemotherapy offer a recurrence and survival benefit in patients with resected perihilar cholangiocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2435-2445.	1.2	11
305	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	1.0	16
306	Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part II: Treatment. <i>Digestive and Liver Disease</i> , 2020, 52, 1430-1442.	0.4	35
307	A systematic review and meta-analysis of caudate lobectomy for treatment of hilar cholangiocarcinoma. <i>European Journal of Surgical Oncology</i> , 2020, 46, 747-753.	0.5	14
308	Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma: A review of the general principles. <i>International Journal of Surgery</i> , 2020, 82, 77-81.	1.1	23
310	Immunotherapies in clinical development for biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 351-363.	1.9	28
311	Oncological Resection for Liver Malignancies. <i>Annals of Surgery</i> , 2022, 275, 182-188.	2.1	10
312	Combined Vascular Resection for Locally Advanced Perihilar Cholangiocarcinoma. <i>Annals of Surgery</i> , 2022, 275, 382-390.	2.1	55

#	ARTICLE	IF	CITATIONS
313	Multiple cholangiocarcinomas in the intrahepatic and extrahepatic biliary tree due to dichloromethane exposure: a case report. <i>Surgical Case Reports</i> , 2020, 6, 79.	0.2	3
314	Diagnostic-therapeutic management of bile duct cancer. <i>World Journal of Clinical Cases</i> , 2019, 7, 1732-1752.	0.3	18
315	BRAZILIAN CONSENSUS ON INCIDENTAL GALLBLADDER CARCINOMA. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2020, 33, e1496.	0.5	18
316	Evaluation and management of incidental gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 37-37.	0.4	13
317	Adjuvant therapy for resected gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 39-39.	0.4	7
318	Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy. <i>Chinese Clinical Oncology</i> , 2020, 9, 4-4.	0.4	14
319	Independent Risk Factors of Early Recurrence After Curative Resection for Perihilar Cholangiocarcinoma: Adjuvant Chemotherapy May Be Beneficial in Early Recurrence Subgroup. <i>Cancer Management and Research</i> , 2020, Volume 12, 13111-13123.	0.9	5
320	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). <i>Future Oncology</i> , 2020, 16, 1069-1081.	1.1	15
321	Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. <i>Ecancermedicalscience</i> , 2020, 14, 1048.	0.6	7
322	Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. <i>Journal of Clinical Medicine</i> , 2021, 10, 104.	1.0	24
323	Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 3542-3561.	1.4	35
324	Real world clinical outcomes of adjuvant sequential chemoradiation in patients with gallbladder carcinomas with poor performance status. <i>Radiation Oncology Journal</i> , 2020, 38, 262-269.	0.7	2
325	High Systemic Inflammation Response Index (SIRI) Indicates Poor Outcome in Gallbladder Cancer Patients with Surgical Resection: A Single Institution Experience in China. <i>Cancer Research and Treatment</i> , 2020, 52, 1199-1210.	1.3	19
326	Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. <i>World Journal of Hepatology</i> , 2020, 12, 693-708.	0.8	46
328	Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1336-1366.	0.8	10
329	Current State of Multidisciplinary Treatment in Cholangiocarcinoma. <i>Digestive Diseases</i> , 2022, 40, 581-595.	0.8	7
330	Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 262-271.	0.8	59
331	A novel online calculator to predict recurrence risk in patients with distal cholangiocarcinoma after radical pancreaticoduodenectomy. <i>Journal of Surgical Oncology</i> , 2022, 125, 377-386.	0.8	6

#	ARTICLE	IF	CITATIONS
332	Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy Combined with Radical Surgery and Capecitabine on Stage III Gallbladder Cancer. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-7.	0.8	6
333	Gallbladder cancer: Historical treatment and new management options. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1317-1335.	0.8	14
334	Development and validation of an online calculator to predict early recurrence and long-term survival in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 1214-1225.	1.4	7
335	Recurrent Intrahepatic Cholangiocarcinoma – Review. <i>Frontiers in Oncology</i> , 2021, 11, 776863.	1.3	19
337	Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. <i>Lancet Oncology</i> , The, 2021, 22, 1560-1572.	5.1	118
338	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. <i>Aging</i> , 2021, 13, 23416-23434.	1.4	17
339	The role of lymph node dissection in intrahepatic cholangiocarcinoma: a multicenter retrospective study. <i>BMC Surgery</i> , 2021, 21, 359.	0.6	13
341	Combined treatment for locally advanced cholangiocellular liver cancer - the case report. <i>Issledovaniya I Praktika V Medicine</i> , 2019, 6, 158-167.	0.1	1
342	Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma. <i>Hepatic Medicine: Evidence and Research</i> , 2021, Volume 13, 93-104.	0.9	2
344	How to read a published clinical trial: A practical guide for clinicians. <i>Avicenna Journal of Medicine</i> , 2020, 10, 68.	0.3	0
347	Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. <i>Cancer Control</i> , 2020, 27, 107327482098301.	0.7	13
348	Gallbladder Cancer. , 2020, , 183-197.		0
349	Targeted therapies in cholangiocarcinoma: emerging hope through novel trial design. <i>British Journal of Surgery</i> , 2022, 109, 239-241.	0.1	0
350	Gallbladder Cancer: Adjuvant and Palliative Treatment during Covid-19 Pandemic in India. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 132-134.	0.1	0
351	Surgical management of intrahepatic cholangiocarcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 27-38.	1.1	16
352	Comment on “Number and Station of Lymph Node Metastasis After Curative-Intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis”: <i>Annals of Surgery</i> , 2021, 274, e742-e743.	2.1	1
353	Combined treatment options for resectable common bile duct cancer patients. <i>Annals of HPB Surgery</i> , 2020, 25, 123-130.	0.1	0
354	Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy. <i>Oncotarget</i> , 2020, 11, 4195-4200.	0.8	2

#	ARTICLE	IF	CITATIONS
355	Recent advances in understanding cholangiocarcinoma. Faculty Reviews, 2020, 9, 15.	1.7	0
356	Short- and Long-Term Outcomes of Simultaneous Hepatic Artery Resection and Reconstruction for Perihilar Cholangiocarcinoma. Gastrointestinal Tumors, 2021, 8, 25-32.	0.3	0
357	Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors. American Journal of Translational Research (discontinued), 2021, 13, 8598-8610.	0.0	1
358	Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers, 2021, 13, 5709.	1.7	3
359	Image-Guided Local Treatment for Unresectable Intrahepatic Cholangiocarcinoma—Role of Interventional Radiology. Journal of Clinical Medicine, 2021, 10, 5574.	1.0	3
360	A novel method for predicting perineural invasion of distal cholangiocarcinoma on multidetector-row computed tomography. Surgery Today, 2022, 52, 774-782.	0.7	3
361	Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. American Journal of Transplantation, 2022, 22, 823-832.	2.6	41
362	Multimodality management of gallbladder cancer can lead to a better outcome: Experience from a tertiary care oncology centre in North India. World Journal of Gastroenterology, 2021, 27, 7813-7830.	1.4	3
363	Assessment of robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect. Hepatobiliary Surgery and Nutrition, 2021, .	0.7	0
365	Onkologika. , 2021, , 579-638.		0
366	Editorial comment on: development and external validation of a model to predict overall survival in patients with resected gallbladder cancer. Hepatobiliary Surgery and Nutrition, 2021, 11, 0-0.	0.7	0
367	Exosome-based rare earth nanoparticles for targeted <i>in situ</i> and metastatic tumor imaging with chemo-assisted immunotherapy. Biomaterials Science, 2022, 10, 744-752.	2.6	5
368	Short- and Long-Term Outcomes of Simultaneous Hepatic Artery Resection and Reconstruction for Perihilar Cholangiocarcinoma. Gastrointestinal Tumors, 2021, 8, 25-32.	0.3	2
369	Recent advances in understanding cholangiocarcinoma. Faculty Reviews, 2020, 9, 15.	1.7	1
370	Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature. Frontiers in Oncology, 2022, 12, 832405.	1.3	7
371	Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	0
372	Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opinion on Therapeutic Targets, 2022, 26, 79-92.	1.5	4
373	Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma. British Journal of Cancer, 2022, 126, 1280-1288.	2.9	4

#	ARTICLE	IF	CITATIONS
374	Circulating Cell-Free DNA-Based Comprehensive Molecular Analysis of Biliary Tract Cancers Using Next-Generation Sequencing. <i>Cancers</i> , 2022, 14, 233.	1.7	10
375	Feasibility and Safety of Laparoscopic Gallbladder Resection for Gallbladder Tumours. <i>Anticancer Research</i> , 2022, 42, 903-910.	0.5	6
376	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	1.8	15
377	Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach. <i>Cancers</i> , 2022, 14, 362.	1.7	29
378	Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 2393-2405.	0.7	7
379	Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma—Stereotactic radiofrequency ablation as a valuable addition to hepatic resection. <i>PLoS ONE</i> , 2022, 17, e0261136.	1.1	5
380	Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. <i>Scientific Reports</i> , 2022, 12, 1011.	1.6	12
382	Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. <i>Future Oncology</i> , 2022, , .	1.1	1
383	Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study. <i>Hpb</i> , 2022, 24, 1433-1442.	0.1	8
384	The new insight of treatment in Cholangiocarcinoma. <i>Journal of Cancer</i> , 2022, 13, 450-464.	1.2	18
385	Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 553-563.	0.7	9
386	Survival Predictors of Resectable Gallbladder Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. <i>American Surgeon</i> , 2023, 89, 1629-1637.	0.4	4
387	How I treat biliary tract cancer. <i>ESMO Open</i> , 2022, 7, 100378.	2.0	45
388	Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force. <i>Annals of Oncology</i> , 2022, 33, 126-128.	0.6	12
389	Potential molecular target screening and bioinformatics analysis of cholangiocarcinoma based on GEO database. <i>World Chinese Journal of Digestology</i> , 2022, 30, 128-135.	0.0	0
390	Correlation Between Adjuvant Chemotherapy Regimen, Recurrence Pattern and Prognosis of Cholangiocarcinoma After Radical Surgery. <i>Frontiers in Oncology</i> , 2022, 12, 695228.	1.3	3
393	Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis. <i>Lancet Regional Health - Europe</i> , The, 2022, 15, 100324.	3.0	7
395	Prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: multicentre study. <i>British Journal of Surgery</i> , 2022, 109, 610-616.	0.1	13

#	ARTICLE	IF	CITATIONS
396	A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer. <i>JAMA Network Open</i> , 2022, 5, e2146912.	2.8	12
397	Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma. <i>Liver Cancer</i> , 2022, 11, 290-314.	4.2	30
398	Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma. <i>BMC Cancer</i> , 2022, 22, 219.	1.1	4
399	Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report. <i>Surgical Case Reports</i> , 2022, 8, 29.	0.2	1
400	Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022. <i>Cancers</i> , 2022, 14, 1249.	1.7	9
401	Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery. <i>Frontiers in Oncology</i> , 2022, 12, 771688.	1.3	2
402	Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy. <i>JAMA Oncology</i> , 2022, 8, 553.	3.4	21
404	Selumetinib: a selective MEK1 inhibitor for solid tumor treatment. <i>Clinical and Experimental Medicine</i> , 2023, 23, 229-244.	1.9	10
405	Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 1026.	1.7	17
406	Systematic Review and Meta-Analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection. <i>Annals of Surgical Oncology</i> , 2022, 29, 4337-4353.	0.7	18
407	Robotic Surgery for Biliary Tract Cancer. <i>Cancers</i> , 2022, 14, 1046.	1.7	6
408	Treatment of Resectable Gallbladder Cancer. <i>Cancers</i> , 2022, 14, 1413.	1.7	11
409	Intrahepatic Cholangiocarcinoma With Neither Intrahepatic Metastasis Nor Lymph Node Metastasis Is the Optimal Indication for Hepatectomy With Adjuvant Therapy. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 160-166.	0.3	1
410	Textbook outcome after major hepatectomy for perihilar cholangiocarcinoma – definitions and influencing factors. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1561-1573.	0.8	10
411	Targeted Therapies for Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 1789.	1.7	7
412	Camrelizumab Combined With Gemcitabine and Albumin-Bound Paclitaxel for Neoadjuvant Therapy in the Treatment of Progressive Gallbladder Cancer: A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 818626.	1.3	2
413	Multiparametric Magnetic Resonance Imaging Improves the Prognostic Outcomes in Patients With Intrahepatic Cholangiocarcinoma After Curative-Intent Resection. <i>Frontiers in Oncology</i> , 2022, 12, 756726.	1.3	3
414	Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	3

#	ARTICLE	IF	CITATIONS
415	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2048-2057.	0.8	65
416	DWI-based radiomic signature: potential role for individualized adjuvant chemotherapy in intrahepatic cholangiocarcinoma after partial hepatectomy. <i>Insights Into Imaging</i> , 2022, 13, 37.	1.6	3
417	Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review. <i>International Cancer Conference Journal</i> , 0, , 1.	0.2	1
418	Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models. <i>Frontiers in Oncology</i> , 2022, 12, 850732.	1.3	9
420	Incidence Trend and Competing Risk Analysis of Patients With Intrahepatic Cholangiocarcinoma: A Population-Based Study. <i>Frontiers in Medicine</i> , 2022, 9, 846276.	1.2	9
421	Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. <i>European Journal of Cancer</i> , 2022, 164, 80-87.	1.3	12
422	Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments. <i>Cancers</i> , 2022, 14, 1800.	1.7	7
423	Promising Genomic Testing for Biliary Tract Cancer Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration/Biopsy Specimens. <i>Diagnostics</i> , 2022, 12, 900.	1.3	3
424	Perihilar cholangiocarcinoma: a surgeon's perspective. , 2022, 1, 12-24.		1
425	The 11th revision of the International Statistical Classification of Disease and Related Health Problems and Cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 276-279.	0.7	1
426	Biliäre Karzinome: Zielstrukturen für eine molekulare Systemtherapie. , 0, , .		0
427	Neoadjuvant therapy trials in biliary tract malignancies. <i>Journal of Surgical Oncology</i> , 2022, 125, 84-88.	0.8	4
428	Adjuvant chemotherapy for perihilar cholangiocarcinoma: A population-based comparative cohort study. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1300-1308.	0.5	6
429	Adjuvant therapy for intrahepatic carcinoma after surgical resection: chemotherapy and future perspectives. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 878-880.	0.7	1
430	Importance of Normalization of Carbohydrate Antigen 19-9 in Patients With Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 780455.	1.3	4
431	Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 473-481.	0.9	1
432	Minimally invasive surgical treatment of intrahepatic cholangiocarcinoma: A systematic review. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2203-2215.	0.8	13
433	Moving forward in the treatment of cholangiocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1939-1955.	0.8	4

#	ARTICLE	IF	CITATIONS
434	Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile. <i>Life</i> , 2022, 12, 48.	1.1	49
435	Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: far from a clinical consensus. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 887-889.	0.7	3
436	Insights From the Analysis of Clinicopathological and Prognostic Factors in Patients With Gallbladder Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 889334.	1.3	1
437	Gallbladder Cancer: A Single-Institution 10-Year Experience—Analysis of Adenocarcinoma Subtypes and Tumors Arising from Intracholecystic Papillary Neoplasms. <i>Annals of Surgical Oncology</i> , 2022, 29, 5167-5175.	0.7	2
438	The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 492-500.	0.6	3
439	The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1188-1195.	1.0	3
440	Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis. <i>BMJ Open</i> , 2022, 12, e051421.	0.8	1
441	Highlights from the 2022 ASCO Gastrointestinal Cancer Symposium: an overview by the EORTC Gastrointestinal Tract Cancer Group. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	0
442	Updates in Cholangiocarcinoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 320-323.	0.2	4
443	PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 2190.	1.7	4
444	Systematic review of squamous cell carcinoma of the gallbladder. <i>American Journal of Surgery</i> , 2022, 224, 863-868.	0.9	2
445	Changing Landscape of Systemic Therapy in Biliary Tract Cancer. <i>Cancers</i> , 2022, 14, 2137.	1.7	18
446	Adenosquamous carcinoma of gallbladder associated with biliopancreatic maljunction and Todani 1c choledochal cyst: A Case Report. <i>Advances in Digestive Medicine</i> , 0, , .	0.1	1
447	Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2022, 157, 590.	2.2	25
448	Spread of lymph node metastasis and adjuvant therapy for distal cholangiocarcinoma. <i>International Journal of Clinical Oncology</i> , 2022, , .	1.0	0
449	Anatomic patterns of recurrence in biliary tract cancers: does primary tumor site matter?. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1413-1422.	0.6	1
450	Predicting prognosis and evaluating the benefits of adjuvant chemotherapy depending on the tumor location in intrahepatic cholangiocarcinoma: focusing on the involvement of below 2nd bile duct confluence. <i>Annals of Surgical Treatment and Research</i> , 2022, 102, 248.	0.4	0
451	Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, , .	1.6	2

#	ARTICLE	IF	CITATIONS
452	Lymphadenectomy and margin-negative resection for biliary tract cancer surgery in the United States—Differential technical performance by approach. <i>Journal of Surgical Oncology</i> , 2022, , .	0.8	3
453	CT-based deep learning enables early postoperative recurrence prediction for intrahepatic cholangiocarcinoma. <i>Scientific Reports</i> , 2022, 12, 8428.	1.6	15
454	Contrast-enhanced CT radiomics for prediction of recurrence-free survival in gallbladder carcinoma after surgical resection. <i>European Radiology</i> , 2022, 32, 7087-7097.	2.3	9
456	The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study. , 2023, 40, 65-77.		1
458	The Prognostic Relevance of Preoperative CEA and CA19-9 for Ampulla of Vater Carcinoma. <i>Anticancer Research</i> , 2022, 42, 3169-3176.	0.5	1
459	Liver Resection for Type IV Perihilar Cholangiocarcinoma: Left or Right Trisectionectomy?. <i>Cancers</i> , 2022, 14, 2791.	1.7	3
461	Treatment of biliary tract carcinoma over the last 30 years. <i>BioScience Trends</i> , 2022, 16, 189-197.	1.1	2
462	Trends in Primary Gallbladder Cancer Incidence and Incidence-based Mortality in the United States, 1973 to 2015. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 306-315.	0.6	4
463	Using Machine Learning to Preoperatively Stratify Prognosis among Patients with Gallbladder Cancer: A Multi-Institutional Analysis. <i>Hpb</i> , 2022, , .	0.1	1
464	Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. <i>ESMO Open</i> , 2022, 7, 100503.	2.0	8
465	Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
466	Does Caudate Resection Improve Outcomes of Patients Undergoing Curative Resection for Perihilar Cholangiocarcinoma? A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 6759-6771.	0.7	5
467	Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. <i>Journal of Hepatology</i> , 2022, 77, 1047-1058.	1.8	7
469	Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review. <i>Cureus</i> , 2022, , .	0.2	2
470	Does Intraoperative Frozen Section and Revision of Margins Lead to Improved Survival in Patients Undergoing Resection of Perihilar Cholangiocarcinoma? A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 7592-7602.	0.7	6
471	Prognostic Utility of Systemic Immune-Inflammation Index After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium. <i>Annals of Surgical Oncology</i> , 2022, 29, 7605-7614.	0.7	7
472	The focus clinical research in intrahepatic cholangiocarcinoma. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	7
473	Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping. <i>Cancers</i> , 2022, 14, 3284.	1.7	11

#	ARTICLE	IF	CITATIONS
474	Postoperative recurrent patterns of gallbladder cancer: possible implications for adjuvant therapy. <i>Radiation Oncology</i> , 2022, 17, .	1.2	4
475	Update on Biliary Cancer Imaging. <i>Radiologic Clinics of North America</i> , 2022, 60, 825-842.	0.9	3
476	Factors of Early Recurrence After Resection for Intrahepatic Cholangiocarcinoma. <i>World Journal of Surgery</i> , 2022, 46, 2459-2467.	0.8	3
477	Preoperative Assessment and Perioperative Management of Resectable Gallbladder Cancer in the Era of Precision Medicine and Novel Technologies: State of the Art and Future Perspectives. <i>Diagnostics</i> , 2022, 12, 1630.	1.3	3
478	Evaluation of abnormal gallbladder imaging findings: Surgical management and pathologic correlations in early-stage gallbladder cancer. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	0
479	Update on Cholangiocarcinoma. <i>Digestive Disease Interventions</i> , 0, , .	0.3	0
480	Identification of publication characteristics and research trends in the management of gallbladder cancer. , 2022, 1, 127-138.		0
482	Ginsenoside Rh4 Suppresses Metastasis of Esophageal Cancer and Expression of c-Myc via Targeting the Wnt/ β 2-Catenin Signaling Pathway. <i>Nutrients</i> , 2022, 14, 3042.	1.7	9
483	Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periapillary Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2023, 30, 165-174.	0.7	9
484	Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211153.	1.4	4
485	Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies. <i>International Journal of Biological Sciences</i> , 2022, 18, 5369-5390.	2.6	14
486	Therapeutic Effect of Regional Chemotherapy in Diffuse Metastatic Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 3701.	1.7	0
487	Tumor budding may be a promising prognostic indicator in intrahepatic cholangiocarcinoma: A multicenter retrospective study. <i>Annals of Gastroenterological Surgery</i> , 2023, 7, 138-146.	1.2	6
488	Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
490	Stereotactic radiotherapy for intrahepatic cholangiocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1478-1489.	0.8	4
491	Converted-hepatopancreatoduodenectomy for an intraoperative positive ductal margin after pancreatoduodenectomy in distal cholangiocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 0, , .	0.8	2
492	Serum Levels of CXCL13 Are an Independent Predictor of Survival Following Resection of Biliary Tract Cancer. <i>Cancers</i> , 2022, 14, 4073.	1.7	2
493	Risk factors and prognosis of liver metastasis in gallbladder cancer patients: A SEER-based study. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	1

#	ARTICLE	IF	CITATIONS
494	Current epidemiology of cholangiocarcinoma in Western countries. <i>Journal of Hepatology</i> , 2022, 77, 1690-1698.	1.8	39
495	Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine. <i>Translational Oncology</i> , 2022, 25, 101514.	1.7	11
496	Application of Hazard Function to Investigate Recurrence of Intrahepatic Cholangiocarcinoma After Curative-Intent Liver Resection: A Novel Approach to Characterize Recurrence. <i>Annals of Surgical Oncology</i> , 2023, 30, 1340-1349.	0.7	5
497	Molecular diagnostics and biomarkers in cholangiocarcinoma. <i>Surgical Oncology</i> , 2022, 44, 101851.	0.8	3
499	AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. <i>Hepatology</i> , 2023, 77, 659-702.	3.6	68
500	Golgi Protein 73 (GP73) Serum Levels Predict Outcome after Resection of Biliary Tract Cancer. <i>Cancers</i> , 2022, 14, 4428.	1.7	1
501	Nonsurgical Management of Cholangiocarcinoma. , 2022, , 307-323.		0
502	Nonsurgical Management of Gallbladder Cancer. , 2022, , 387-394.		0
503	Lymph Node Ratio Nomogram-Based Prognostic Model for Resected Distal Cholangiocarcinoma. <i>Journal of the American College of Surgeons</i> , 2022, 235, 703-712.	0.2	2
504	Surgical Treatment of Distal Cholangiocarcinoma. <i>Current Oncology</i> , 2022, 29, 6674-6687.	0.9	6
505	Systemic Therapy Is Associated with Improved Oncologic Outcomes in Resectable Stage II/III Intrahepatic Cholangiocarcinoma: An Examination of the National Cancer Database over the Past Decade. <i>Cancers</i> , 2022, 14, 4320.	1.7	1
506	Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective. <i>Current Oncology</i> , 2022, 29, 7072-7085.	0.9	5
507	Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
508	A Multicenter, Randomized, Double-Blinded, Clinical Trial Comparing Cattell-Warren and Blumgart Anastomoses Following Partial Pancreatoduodenectomy. <i>Annals of Surgery Open</i> , 2022, 3, e198.	0.7	4
509	Rational development of combination therapies for biliary tract cancers. <i>Journal of Hepatology</i> , 2023, 78, 217-228.	1.8	15
510	Feasibility and Efficacy of Adjuvant Chemotherapy With Gemcitabine After Liver Transplantation for Perihilar Cholangiocarcinoma - A Multi-Center, Randomized, Controlled Trial (pro-duct001). <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
511	Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan. <i>Current Oncology</i> , 2022, 29, 7272-7284.	0.9	4
512	R1 Vascular or Parenchymal Margins: What Is the Impact after Resection of Intrahepatic Cholangiocarcinoma?. <i>Cancers</i> , 2022, 14, 5151.	1.7	1

#	ARTICLE	IF	CITATIONS
513	Selective Internal Radiation Therapy (Yttrium-90 Glass Microspheres) Combined with Capecitabine in the Neoadjuvant Setting of Operable Intrahepatic CHolangiocarcinoma: The SIROCHO Trial Design. <i>Annals of Surgical Oncology</i> , 2023, 30, 21-22.	0.7	1
514	The Long-Term Outcome of Laparoscopic Resection for Perihilar Cholangiocarcinoma Compared with the Open Approach: A Real-World Multicentric Analysis. <i>Annals of Surgical Oncology</i> , 2023, 30, 1366-1378.	0.7	8
515	The clinical outcomes of extended resections in patients with IV stage gallbladder cancers: A retrospective study from a large tertiary center. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
516	Gallbladder cancer. <i>Nature Reviews Disease Primers</i> , 2022, 8, .	18.1	68
517	Long-term morbidity after surgery for perihilar cholangiocarcinoma: A cohort study. <i>Surgical Oncology</i> , 2022, 45, 101875.	0.8	1
520	Past, Present, and Future Management of Localized Biliary Tract Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2023, 32, 83-99.	0.6	3
521	Predictive risk-score model to select patients with intrahepatic cholangiocarcinoma for adjuvant chemotherapy. <i>Hpb</i> , 2023, 25, 229-238.	0.1	0
522	Development and validation of a prognostic nomogram for extrahepatic bile duct adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
523	Liver transplantation and intrahepatic cholangiocarcinoma: time to go forward again?. <i>Current Opinion in Organ Transplantation</i> , 2022, 27, 320-328.	0.8	2
524	Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions. <i>Cancers</i> , 2022, 14, 5580.	1.7	15
525	Preoperative Serum Markers and Risk Classification in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Study. <i>Cancers</i> , 2022, 14, 5459.	1.7	2
526	A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
527	Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 127-140.	0.6	119
528	Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
530	Combined hepatocellular carcinoma-cholangiocarcinoma in a patient with Fontan-associated liver disease. <i>BMJ Case Reports</i> , 2022, 15, e250590.	0.2	1
531	Circular RNAs in cholangiocarcinoma. <i>Cancer Letters</i> , 2023, 553, 215980.	3.2	11
532	Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment. <i>Cells</i> , 2022, 11, 3613.	1.8	3
533	Potential Role of Surgical Resection for Gallbladder Cancer in Elderly Patients. <i>American Surgeon</i> , 2023, 89, 5118-5123.	0.4	1

#	ARTICLE	IF	CITATIONS
534	Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. <i>ESMO Open</i> , 2023, 8, 100604.	2.0	5
535	Impact of Preoperative Jaundice and Biliary Drainage on Short- and Long-term Outcomes among Patients with Gallbladder Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2023, 27, 105-113.	0.9	2
536	Impact of the Affordable Care Act on Presentation, Treatment, and Outcomes of Intrahepatic Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2023, 27, 262-272.	0.9	5
537	Impact of adjuvant therapy on outcomes after curative-intent resection for distal cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 0, , .	0.8	1
538	Rare histotypes of epithelial biliary tract tumors: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103892.	2.0	5
539	Adjuvant treatment for the elderly patient with resected gallbladder cancer: a SEER-Medicare analysis. <i>Journal of Gastrointestinal Oncology</i> , 2022, .	0.6	0
540	Enhanced Recovery in Liver Surgery. , 2022, , 529-535.		0
542	Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update. <i>Intractable and Rare Diseases Research</i> , 2022, 11, 161-172.	0.3	5
543	Establishment and validation of a prognostic nomogram for extrahepatic cholangiocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
544	Locoregional Approaches in Cholangiocarcinoma Treatment. <i>Cancers</i> , 2022, 14, 5853.	1.7	5
546	Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
547	What is the management of resected cholangiocarcinoma in terms of intra- and postoperative status of tumor margins and lymph nodes? A current view. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 1019-1022.	1.4	0
548	Elevated Serum Levels of CCL23 Are Associated with Poor Outcome after Resection of Biliary Tract Cancer. <i>Mediators of Inflammation</i> , 2022, 2022, 1-9.	1.4	2
549	American Radium Society (ARS) Appropriate Use Criteria (AUC) for Extrahepatic Cholangiocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, Publish Ahead of Print, .	0.6	0
550	Surgical Aspects of Intrahepatic Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 6265.	1.7	6
551	Does Adjuvant Therapy Benefit Low-Risk Resectable Cholangiocarcinoma? An Evaluation of the NCCN Guidelines. <i>Journal of Gastrointestinal Surgery</i> , 2023, 27, 511-520.	0.9	2
552	Adjuvant Chemoradiation in Patients with Lymph Node-Positive Biliary Tract Cancers: Secondary Analysis of a Single-Arm Clinical Trial (SWOG 0809). <i>Annals of Surgical Oncology</i> , 2023, 30, 1354-1363.	0.7	6
553	Prognostic influence of multiple hepatic lesions in resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2023, , .	0.5	2

#	ARTICLE	IF	CITATIONS
554	Survival analysis of extrahepatic cholangiocarcinoma based on surveillance, epidemiology, and end results database. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2023, 27, 151-157.	0.1	2
555	Pharmacokinetics and Comparative Bioavailability of Test or Reference Capecitabine and Discrepant Pharmacokinetics Among Various Tumors in Chinese Solid Cancer Patients. <i>Clinical Pharmacology in Drug Development</i> , 0, , .	0.8	1
556	Prognostic nomogram for cancer-specific survival in patients with intrahepatic cholangiocarcinoma after hepatectomy: A population study of 919 patients. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	2
557	Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD. <i>Biomedicine and Pharmacotherapy</i> , 2023, 159, 114232.	2.5	6
558	Gallbladder Cancer: Diagnosis and Surgical Management. , 0, , .		0
559	Survival after extended resections for gallbladder cancer. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2023, 27, 70-75.	0.1	1
560	The epidemiological trends of biliary tract cancers in the United States of America. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	12
561	Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
562	A Look at Emerging Therapeutic Targets for Gallbladder Cancer: A Multi-Omics Approach. , 2023, , 161-175.		0
563	Targeted Treatment of Gallbladder Cancer. , 2023, , 237-247.		0
564	Adjuvant Therapy in Gallbladder Cancers. , 2023, , 145-157.		0
565	Surgical Management of Gallbladder Cancer Patients. , 2023, , 33-58.		0
566	Adjuvant therapy in biliary tract cancers: oral fluoropyrimidine as a beginning. <i>Lancet, The</i> , 2023, 401, 170-171.	6.3	0
567	Molecular Pathways in Gallbladder Cancer as Potential Therapeutic Target. , 2023, , 249-268.		0
568	Whole-genome sequencing of 20 cholangiocarcinoma cases reveals unique profiles in patients with cirrhosis and primary sclerosing cholangitis. <i>Journal of Gastrointestinal Oncology</i> , 2023, 14, 379-389.	0.6	1
569	Gallbladder Cancer: Current Treatment Options and Therapeutics. , 2023, , 3-30.		0
570	Hepatic artery resection in distal cholangiocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, .	0.8	0
571	Management of Incidentally Detected Gallbladder Cancer After Cholecystectomy. , 2023, , 123-144.		1

#	ARTICLE	IF	CITATIONS
572	Adjuvant Therapy of Gallbladder Cancer. , 2023, , 75-88.		0
573	Adjuvant treatment for biliary tract tumors: lost in a maze?. Hepatology, 2023, 77, 1465-1468.	3.6	0
574	A preoperative scoring system to predict lymph node metastasis in intrahepatic cholangiocarcinoma. Hepatology International, 2023, 17, 942-953.	1.9	1
575	Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet, The, 2023, 401, 195-203.	6.3	59
576	Accepting Our Technical Limitations: Intraoperative Bile Duct Margin in Perihilar Cholangiocarcinoma Reflects Disease Biology. Annals of Surgical Oncology, 0, , .	0.7	0
577	Role of Intraoperative Assessment of Proximal Bile Duct Margin Status and Additional Resection of Perihilar Cholangiocarcinoma: Can Local Clearance Trump Tumor Biology? A Retrospective Cohort Study. Annals of Surgical Oncology, 2023, 30, 3348-3359.	0.7	5
578	Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. Targeted Oncology, 2023, 18, 51-76.	1.7	2
579	Characteristics and outcomes of gallbladder cancer patients at the Tata Medical Center, Kolkata 2017â€“2019. Cancer Medicine, 0, , .	1.3	2
580	Multivariable prediction model for both 90-day mortality and long-term survival for individual patients with perihilar cholangiocarcinoma: does the predicted survival justify the surgical risk?. British Journal of Surgery, 2023, 110, 599-605.	0.1	8
581	Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 677-688.	0.8	0
584	HÄmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
585	CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges. Cancers, 2023, 15, 968.	1.7	3
586	Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma. Cancers, 2023, 15, 988.	1.7	1
587	Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 462-480.	8.2	9
588	Diurnal Changes in Capecitabine Clock-Controlled Metabolism Enzymes Are Responsible for Its Pharmacokinetics in Male Mice. Journal of Biological Rhythms, 2023, 38, 171-184.	1.4	2
589	New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy. Cancers, 2023, 15, 1244.	1.7	13
590	A Case of Prostatic Metastasis from Intrahepatic Cholangiocarcinoma: An Extremely Rare Event. Cureus, 2023, , .	0.2	0
591	Emerging treatment strategies in hepatobiliary cancer. Expert Review of Anticancer Therapy, 2023, 23, 243-256.	1.1	1

#	ARTICLE	IF	CITATIONS
592	Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring. <i>Annals of Surgical Oncology</i> , 2023, 30, 3849-3863.	0.7	5
593	Therapeutic response analysis for patients with adenocarcinoma of the gallbladder: data analysis based on the Surveillance, Epidemiology, and End Results (SEER) database. <i>Journal of Gastrointestinal Oncology</i> , 2023, 14, 405-419.	0.6	1
594	Current Perspectives in Liver Transplantation for Perihilar Cholangiocarcinoma. <i>Current Oncology</i> , 2023, 30, 2942-2953.	0.9	1
596	Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy. <i>Cells</i> , 2023, 12, 851.	1.8	2
597	NUF2 Drives Cholangiocarcinoma Progression and Migration via Inhibiting Autophagic Degradation of TFR1. <i>International Journal of Biological Sciences</i> , 2023, 19, 1336-1351.	2.6	2
598	Adjuvant chemoradiotherapy in resected gallbladder cancer: A SEER-based study. <i>Heliyon</i> , 2023, 9, e14574.	1.4	2
599	Adjuvant therapy for cholangiocarcinoma after surgery and prognosis factors for cholangiocarcinoma: A single-center retrospective cohort study. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
600	Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza. <i>Cancers</i> , 2023, 15, 1970.	1.7	5
601	Adjuvant therapy of biliary tract cancers. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311637.	1.4	2
602	Impact of acute cholecystitis comorbidity on prognosis after surgery for gallbladder cancer: a propensity score analysis. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	2
604	Preoperative chemotherapy usage experience for intrahepatic cholangiocarcinoma. <i>Issledovaniã I Praktika V Medicine</i> , 2023, 10, 57-67.	0.1	0
605	Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Pharmaceuticals</i> , 2023, 16, 510.	1.7	0
606	Liver transplantation in the management of cholangiocarcinoma: Evolution and contemporary advances. <i>World Journal of Gastroenterology</i> , 0, 29, 1969-1981.	1.4	3
607	Precision Oncology Targets in Biliary Tract Cancer. <i>Cancers</i> , 2023, 15, 2105.	1.7	5
608	Neoadjuvant Therapy for Extrahepatic Biliary Tract Cancer: A Propensity Score-Matched Survival Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 2654.	1.0	4
610	Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. <i>Journal of the National Cancer Institute</i> , 2023, 115, 870-880.	3.0	4
612	Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	1
613	The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 779-788.	0.9	3

#	ARTICLE	IF	CITATIONS
614	Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. <i>Hepatology</i> , 2023, 77, 1540-1549.	3.6	7
615	Surgical treatment for recurrent cholangiocarcinoma: a single-center series. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
616	EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2023, 79, 181-208.	1.8	33
617	Locoregional Therapy for Intrahepatic Cholangiocarcinoma. <i>Cancers</i> , 2023, 15, 2384.	1.7	6
618	Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer. <i>International Journal of Clinical Pharmacy</i> , 2023, 45, 875-883.	1.0	0
654	Staging and Treatment. , 2023, , 377-389.		0
657	Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial. <i>Hepatology</i> , 2023, 78, E74-E75.	3.6	0
661	Biliary System and Gallbladder. , 2023, , 297-326.		0
670	Lymph Node Dissection in Intrahepatic Cholangiocarcinoma: a Critical and Updated Review of the Literature. <i>Journal of Gastrointestinal Surgery</i> , 2023, 27, 3001-3013.	0.9	1
697	Radiation Therapy for Primary Liver Cancer. , 2023, , 1-17.		0
698	Systemic Treatment for Cholangiocarcinoma. <i>Recent Results in Cancer Research</i> , 2023, , 223-244.	1.8	1
703	Biliary Tract. <i>Hot Topics in Acute Care Surgery and Trauma</i> , 2023, , 189-224.	0.1	0
761	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0